Safe use of platelet GP IIb/IIIa inhibitors (Q74434392)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9539498%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

review article

1 reference

title

Safe use of platelet GP IIb/IIIa inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9539498%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

2

D J Kereiakes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9539498%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

author name string

J J Ferguson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9539498%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

A A Adgey

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9539498%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

K A Fox

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9539498%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

W B Hillegass

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9539498%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

M Pfisterer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9539498%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

C Vassanelli

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9539498%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

language of work or name

English

0 references

publication date

1 April 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9539498%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

published in

American Heart Journal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9539498%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

volume

135

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9539498%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9539498%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

page(s)

S77-89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9539498%20AND%20SRC:MED&resulttype=core&format=json

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

10 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970300-X

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970300-X

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970300-X

Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970300-X

Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complicatio

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970300-X

Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970300-X

Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970300-X

Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970300-X

Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970300-X

Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970300-X

Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina. Results of the TAUSA Trial. TAUSA Investigators. Thrombolysis and Angioplasty in Unstable Angina trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970300-X

Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970300-X

In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970300-X

Partial reversal of heparin anticoagulation by intravenous protamine in abciximab-treated patients undergoing percutaneous intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970300-X

10.1016/S0002-8703(98)70300-X

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9539498%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference